JP2003533175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003533175A5 JP2003533175A5 JP2001538942A JP2001538942A JP2003533175A5 JP 2003533175 A5 JP2003533175 A5 JP 2003533175A5 JP 2001538942 A JP2001538942 A JP 2001538942A JP 2001538942 A JP2001538942 A JP 2001538942A JP 2003533175 A5 JP2003533175 A5 JP 2003533175A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- molecule
- nonapeptide
- cytolytic
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 12
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/440,621 US6417165B1 (en) | 1988-03-27 | 1999-11-15 | NY-ESO-1-peptide derivatives, and uses thereof |
| US09/440,621 | 1999-11-15 | ||
| US09/514,036 US6689742B1 (en) | 2000-02-25 | 2000-02-25 | NY-ESO-1 peptide derivatives, and uses thereof |
| US09/514,036 | 2000-02-25 | ||
| US09/676,005 US6605711B1 (en) | 1999-11-15 | 2000-09-29 | NY-ESO-1 peptide derivatives, and uses thereof |
| US09/676,005 | 2000-09-29 | ||
| PCT/US2000/042010 WO2001036453A2 (en) | 1999-11-15 | 2000-11-08 | Ny-eso-1 nanopeptide derivatives, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003533175A JP2003533175A (ja) | 2003-11-11 |
| JP2003533175A5 true JP2003533175A5 (enExample) | 2006-12-21 |
| JP4615805B2 JP4615805B2 (ja) | 2011-01-19 |
Family
ID=27412062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538942A Expired - Fee Related JP4615805B2 (ja) | 1999-11-15 | 2000-11-08 | Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1230261B1 (enExample) |
| JP (1) | JP4615805B2 (enExample) |
| AU (1) | AU776058B2 (enExample) |
| CA (1) | CA2390659C (enExample) |
| WO (1) | WO2001036453A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923337D0 (en) * | 1999-10-04 | 1999-12-08 | Isis Innovation | Binding agents |
| EP2333065B1 (en) | 2000-01-28 | 2017-03-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MHC class II restricted T cell epitopes from the cancer antigen NY ESO-1 |
| US7547517B2 (en) | 2002-09-27 | 2009-06-16 | Ludwig Institute For Cancer Research | MAGE-C2 antigenic peptides and uses thereof |
| ES2390967T3 (es) * | 2004-01-20 | 2012-11-20 | Aichi Prefecture | Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización |
| EP2332971B1 (en) * | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
| US20160017031A1 (en) * | 2006-06-01 | 2016-01-21 | Receptor Logic, LLC | T cell receptor mimic rl9a |
| JP2018505152A (ja) | 2014-12-23 | 2018-02-22 | アン ブリンブル マーガレット | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
| WO2017145097A2 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| AU2018323043A1 (en) * | 2017-08-30 | 2020-03-05 | Auckland Uniservices Limited | Peptide conjugates, conjugation process, and uses thereof |
| CN112442118B (zh) * | 2019-08-30 | 2023-02-14 | 深圳普瑞金生物药业股份有限公司 | 一种tcr及其应用 |
| US20210369828A1 (en) * | 2020-05-28 | 2021-12-02 | Case Western Reserve University | Plant virus based cancer antigen vaccine |
| WO2025171250A1 (en) * | 2024-02-08 | 2025-08-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Nyeso1 tcr for t-cell therapy and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1021535B1 (en) * | 1997-10-08 | 2007-03-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Human cancer antigen ny eso-1/cag-3 and gene encoding same |
-
2000
- 2000-11-08 JP JP2001538942A patent/JP4615805B2/ja not_active Expired - Fee Related
- 2000-11-08 WO PCT/US2000/042010 patent/WO2001036453A2/en not_active Ceased
- 2000-11-08 AU AU30791/01A patent/AU776058B2/en not_active Ceased
- 2000-11-08 EP EP00990987A patent/EP1230261B1/en not_active Expired - Lifetime
- 2000-11-08 CA CA002390659A patent/CA2390659C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burns et al. | Calcium channel activity of purified human synexin and structure of the human synexin gene. | |
| JP2003533175A5 (enExample) | ||
| Kurepa et al. | Qa-1b binds conserved class I leader peptides derived from several mammalian species | |
| Leberer et al. | Molecular cloning and expression of cDNA encoding a lumenal calcium binding glycoprotein from sarcoplasmic reticulum. | |
| WO2000005249A3 (en) | Synthetic peptides and methods of use for autoimmune disease therapies | |
| JP2002535956A5 (enExample) | ||
| CA2248667A1 (en) | Hla-a2.1 binding peptides and their uses | |
| IL142905A0 (en) | Functional antagonists of hedgehog activity | |
| EP2311955A3 (en) | Osteoprotegerin binding proteins and their receptors | |
| WO2001025793A3 (en) | Diagnosis of coeliac disease using a gliadin epitope | |
| EP0784059A4 (en) | ANTIGENIC POLYPEPTIDE OF CHLAMYDIA PNEUMONIAE | |
| MX9606463A (es) | Secuencias de nucleotido de las cepas pestivirus, polipeptidos codificados por estas secuencias y usos de los mismos para la diagnosis y prevencion de infecciones con pestivirus. | |
| WO2002008426A3 (en) | Fh-binding protein of streptococcus pneumoniae | |
| CA2390659A1 (en) | Ny-eso-1 peptide derivatives, and uses thereof | |
| CA2103551A1 (en) | Method for production of an iga binding protein derived from group b streptococci | |
| WO2002008716A3 (fr) | Procede de criblage de peptides utilisables en immunotherapie | |
| JP2002517193A5 (enExample) | ||
| JPH1075778A5 (enExample) | ||
| Fruci et al. | Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I α chains | |
| RU2001127439A (ru) | Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом | |
| WO2000059942A3 (en) | Human obesity protein binding protrein-2 homolog and uses thereof | |
| WO2002026778A3 (en) | Isolated peptides which bind to hla-c molecules and uses thereof | |
| Schoel et al. | Elongated peptides, not the predicted nonapeptide stimulate a major histocompatibility complex class I‐restricted cytotoxic T lymphocyte clone with specificity for a bacterial heat shock protein | |
| Fruci et al. | The peptide-binding specificity of HLA-B27 subtype (B∗ 2705) analyzed by the use of polyalanine model peptides | |
| EP1842911A4 (en) | HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS |